| http://dbpedia.org/ontology/abstract
|
Finerenona, vendido sob a marca Kerendia, … Finerenona, vendido sob a marca Kerendia, é um medicamento da classe dos antimineralocorticoides usado para diminuir o risco de declínio da função renal, insuficiência renal, morte cardiovascular, ataques cardíacos não fatais e, ainda, em tratamento intensivo por insuficiência cardíaca em pessoas com doença renal crônica associada ao diabetes tipo 2. A finerenona é um antagonista da aldasterona (MRA) não esteroidal, atuando diretamente nos receptores mineralocorticoides. Os efeitos colaterais comuns são hipercalemia (níveis elevados de potássio), hipotensão (pressão arterial baixa) e hiponatremia (níveis baixos de sódio). A finerenona foi aprovada para uso médico nos Estados Unidos em julho de 2021.édico nos Estados Unidos em julho de 2021.
, Il finerenone (INN, USAN) (codice di svilu … Il finerenone (INN, USAN) (codice di sviluppo BAY-94-8862) è un anti-mineralocorticoide non steroideo che è negli studi clinici di fase III per il trattamento dell'insufficienza cardiaca cronica a partire da ottobre 2015. Ha meno affinità relativa rispetto ad altri recettori degli ormoni steroidi. Attualmente disponibili antimineralcorticoidi come eplerenone e spironolattone, che dovrebbero portare a meno effetti negativi come la ginecomastia, l'impotenza e diminuzione del desiderio sessuale.enza e diminuzione del desiderio sessuale.
, La finérénone est un antagoniste non-stéroïdien des récepteurs des minéralocorticoïdes (ARM) en phase III d'essai clinique — en 2015 — pour traiter l'insuffisance cardiaque et la néphropathie diabétique.
, Finerenon ist ein Arzneistoff aus der Grup … Finerenon ist ein Arzneistoff aus der Gruppe der nicht-steroidalen und selektiven Mineralokortikoidrezeptor-Antagonisten (MRA). Unter dem Namen Kerendia (Bayer) wurde er im Juli 2021 in den USA und im Februar 2022 in der EU zugelassen, um renale und kardiovaskuläre Ereignisse bei Patienten mit chronischer Nierenerkrankung (chronic kidney disease, CKD) und Typ-2-Diabetes zu vermindern. Finerenon wird peroral angewendet (eingenommen).non wird peroral angewendet (eingenommen).
, Finerenone, sold under the brand name Kere … Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). Common side effects include hyperkalemia (high levels of potassium), hypotension (low blood pressure), and hyponatremia (low levels of sodium). Finerenone was approved for medical use in the United States in July 2021, and in the European Union in February 2022.nd in the European Union in February 2022.
|
| http://dbpedia.org/ontology/alternativeName
|
Kerendia
|
| http://dbpedia.org/ontology/casNumber
|
1050477-31-0
|
| http://dbpedia.org/ontology/chEMBL
|
2181927
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Potassium-sparing_diuretic +
|
| http://dbpedia.org/ontology/drugbank
|
DB16165
|
| http://dbpedia.org/ontology/fdaUniiCode
|
DE2O63YV8R
|
| http://dbpedia.org/ontology/kegg
|
D10633
|
| http://dbpedia.org/ontology/pubchem
|
60150535
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Finerenone.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/finerenone +
|
| http://dbpedia.org/ontology/wikiPageID
|
48396835
|
| http://dbpedia.org/ontology/wikiPageLength
|
15376
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1122996805
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/Half_maximal_inhibitory_concentration +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Gynaecomastia +
, http://dbpedia.org/resource/Mineralocorticoid_receptor +
, http://dbpedia.org/resource/Steroid_hormone_receptor +
, http://dbpedia.org/resource/Indication_%28medicine%29 +
, http://dbpedia.org/resource/Impotence +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Glucocorticoid_receptor +
, http://dbpedia.org/resource/Medication +
, http://dbpedia.org/resource/Fast_track_%28FDA%29 +
, http://dbpedia.org/resource/Category:Nitriles +
, http://dbpedia.org/resource/Eplerenone +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Spironolactone +
, http://dbpedia.org/resource/Affinity_%28pharmacology%29 +
, http://dbpedia.org/resource/Androgen_receptor +
, http://dbpedia.org/resource/Category:Antimineralocorticoids +
, http://dbpedia.org/resource/Category:Naphthyridines +
, http://dbpedia.org/resource/Chronic_kidney_disease +
, http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Priority_review +
, http://dbpedia.org/resource/Potassium-sparing_diuretic +
, http://dbpedia.org/resource/Hypoactive_sexual_desire_disorder +
, http://dbpedia.org/resource/Non-steroidal +
, http://dbpedia.org/resource/Nanomolar +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Estrogen_receptor +
, http://dbpedia.org/resource/Progesterone_receptor +
, http://dbpedia.org/resource/Diabetic_kidney_disease +
, http://dbpedia.org/resource/Mineralocorticoid_receptor_antagonist +
|
| http://dbpedia.org/property/atcPrefix
|
3.0
|
| http://dbpedia.org/property/atcSuffix
|
DA05
|
| http://dbpedia.org/property/c
|
21
|
| http://dbpedia.org/property/casNumber
|
1050477
|
| http://dbpedia.org/property/chembl
|
2181927
|
| http://dbpedia.org/property/chemspiderid
|
28669387
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Potassium-sparing_diuretic +
|
| http://dbpedia.org/property/dailymedid
|
Finerenone
|
| http://dbpedia.org/property/drugbank
|
DB16165
|
| http://dbpedia.org/property/h
|
22
|
| http://dbpedia.org/property/iupacName
|
-4
|
| http://dbpedia.org/property/kegg
|
D10633
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/n
|
4
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/pregnancyAu
|
D
|
| http://dbpedia.org/property/pubchem
|
60150535
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
NCC1=CNc2ccncc2[C@@H]1c3ccccc3OC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
BTBHLEZXCOBLCY-QGZVFWFLSA-N
|
| http://dbpedia.org/property/synonyms
|
BAY 94-8862
|
| http://dbpedia.org/property/tradename
|
Kerendia
|
| http://dbpedia.org/property/unii
|
DE2O63YV8R
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Full_citation_needed +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:Cite_journal +
, http://dbpedia.org/resource/Template:Diuretics +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Nbsp +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Mineralocorticoid_receptor_modulators +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Mineralocorticoids_and_antimineralocorticoids +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Phenol_ethers +
, http://dbpedia.org/resource/Category:Antimineralocorticoids +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Category:Naphthyridines +
, http://dbpedia.org/resource/Category:Nitriles +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antimineralocorticoid +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Finerenone?oldid=1122996805&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Finerenone.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Finerenone +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q21099046 +
, http://vi.dbpedia.org/resource/Finerenone +
, http://fr.dbpedia.org/resource/Fin%C3%A9r%C3%A9none +
, http://yago-knowledge.org/resource/Finerenone +
, http://dbpedia.org/resource/Finerenone +
, http://sr.dbpedia.org/resource/Finerenon +
, http://de.dbpedia.org/resource/Finerenon +
, http://it.dbpedia.org/resource/Finerenone +
, https://global.dbpedia.org/id/zFxy +
, http://pt.dbpedia.org/resource/Finerenona +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
, http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
|
| rdfs:comment |
Finerenona, vendido sob a marca Kerendia, … Finerenona, vendido sob a marca Kerendia, é um medicamento da classe dos antimineralocorticoides usado para diminuir o risco de declínio da função renal, insuficiência renal, morte cardiovascular, ataques cardíacos não fatais e, ainda, em tratamento intensivo por insuficiência cardíaca em pessoas com doença renal crônica associada ao diabetes tipo 2. A finerenona é um antagonista da aldasterona (MRA) não esteroidal, atuando diretamente nos receptores mineralocorticoides. A finerenona foi aprovada para uso médico nos Estados Unidos em julho de 2021.édico nos Estados Unidos em julho de 2021.
, Finerenon ist ein Arzneistoff aus der Grup … Finerenon ist ein Arzneistoff aus der Gruppe der nicht-steroidalen und selektiven Mineralokortikoidrezeptor-Antagonisten (MRA). Unter dem Namen Kerendia (Bayer) wurde er im Juli 2021 in den USA und im Februar 2022 in der EU zugelassen, um renale und kardiovaskuläre Ereignisse bei Patienten mit chronischer Nierenerkrankung (chronic kidney disease, CKD) und Typ-2-Diabetes zu vermindern. Finerenon wird peroral angewendet (eingenommen).non wird peroral angewendet (eingenommen).
, La finérénone est un antagoniste non-stéroïdien des récepteurs des minéralocorticoïdes (ARM) en phase III d'essai clinique — en 2015 — pour traiter l'insuffisance cardiaque et la néphropathie diabétique.
, Finerenone, sold under the brand name Kere … Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA). Common side effects include hyperkalemia (high levels of potassium), hypotension (low blood pressure), and hyponatremia (low levels of sodium)., and hyponatremia (low levels of sodium).
, Il finerenone (INN, USAN) (codice di svilu … Il finerenone (INN, USAN) (codice di sviluppo BAY-94-8862) è un anti-mineralocorticoide non steroideo che è negli studi clinici di fase III per il trattamento dell'insufficienza cardiaca cronica a partire da ottobre 2015. Ha meno affinità relativa rispetto ad altri recettori degli ormoni steroidi. Attualmente disponibili antimineralcorticoidi come eplerenone e spironolattone, che dovrebbero portare a meno effetti negativi come la ginecomastia, l'impotenza e diminuzione del desiderio sessuale.enza e diminuzione del desiderio sessuale.
|
| rdfs:label |
Finérénone
, Finerenona
, Finerenone
, Finerenon
|
